A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family

CARD11 is a lymphocyte-specific scaffold molecule required for proper activation of B- and T-cells in response to antigen. Germline gain-of-function (GOF) mutations in the CARD11 gene cause a unique B cell lymphoproliferative disorder known as B cell Expansion with NF-κB and T cell Anergy (BENTA). I...

Full description

Bibliographic Details
Main Authors: Marylin Desjardins, Swadhinya Arjunaraja, Jeffrey R. Stinson, Batsukh Dorjbal, Janani Sundaresan, Julie Niemela, Mark Raffeld, Helen F. Matthews, Angela Wang, Pamela Angelus, Helen C. Su, Bruce D. Mazer, Andrew L. Snow
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-12-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02944/full
id doaj-27da10c6f70a47b49f5c81ba79866af4
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Marylin Desjardins
Marylin Desjardins
Swadhinya Arjunaraja
Jeffrey R. Stinson
Batsukh Dorjbal
Janani Sundaresan
Julie Niemela
Mark Raffeld
Helen F. Matthews
Angela Wang
Angela Wang
Pamela Angelus
Pamela Angelus
Helen C. Su
Bruce D. Mazer
Bruce D. Mazer
Andrew L. Snow
spellingShingle Marylin Desjardins
Marylin Desjardins
Swadhinya Arjunaraja
Jeffrey R. Stinson
Batsukh Dorjbal
Janani Sundaresan
Julie Niemela
Mark Raffeld
Helen F. Matthews
Angela Wang
Angela Wang
Pamela Angelus
Pamela Angelus
Helen C. Su
Bruce D. Mazer
Bruce D. Mazer
Andrew L. Snow
A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family
Frontiers in Immunology
CARD11
BENTA
Atopy
B cell lymphocytosis
primary immumunodeficiencies
author_facet Marylin Desjardins
Marylin Desjardins
Swadhinya Arjunaraja
Jeffrey R. Stinson
Batsukh Dorjbal
Janani Sundaresan
Julie Niemela
Mark Raffeld
Helen F. Matthews
Angela Wang
Angela Wang
Pamela Angelus
Pamela Angelus
Helen C. Su
Bruce D. Mazer
Bruce D. Mazer
Andrew L. Snow
author_sort Marylin Desjardins
title A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family
title_short A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family
title_full A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family
title_fullStr A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family
title_full_unstemmed A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation Family
title_sort unique heterozygous card11 mutation combines pathogenic features of both gain- and loss-of-function patients in a four-generation family
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2018-12-01
description CARD11 is a lymphocyte-specific scaffold molecule required for proper activation of B- and T-cells in response to antigen. Germline gain-of-function (GOF) mutations in the CARD11 gene cause a unique B cell lymphoproliferative disorder known as B cell Expansion with NF-κB and T cell Anergy (BENTA). In contrast, patients carrying loss-of-function (LOF), dominant negative (DN) CARD11 mutations present with severe atopic disease. Interestingly, both GOF and DN CARD11 variants cause primary immunodeficiency, with recurrent bacterial and viral infections, likely resulting from impaired adaptive immune responses. This report describes a unique four-generation family harboring a novel heterozygous germline indel mutation in CARD11 (c.701-713delinsT), leading to one altered amino acid and a deletion of 4 others (p.His234_Lys238delinsLeu). Strikingly, affected members exhibit both moderate B cell lymphocytosis and atopic dermatitis/allergies. Ectopic expression of this CARD11 variant stimulated constitutive NF-κB activity in T cell lines, similar to other BENTA patient mutations. However, unlike other GOF mutants, this variant significantly impeded the ability of wild-type CARD11 to induce NF-κB activation following antigen receptor ligation. Patient lymphocytes display marked intrinsic defects in B cell differentiation and reduced T cell responsiveness in vitro. Collectively, these data imply that a single heterozygous CARD11 mutation can convey both GOF and DN signaling effects, manifesting in a blended BENTA phenotype with atopic features. Our findings further emphasize the importance of balanced CARD11 signaling for normal immune responses.
topic CARD11
BENTA
Atopy
B cell lymphocytosis
primary immumunodeficiencies
url https://www.frontiersin.org/article/10.3389/fimmu.2018.02944/full
work_keys_str_mv AT marylindesjardins auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT marylindesjardins auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT swadhinyaarjunaraja auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT jeffreyrstinson auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT batsukhdorjbal auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT jananisundaresan auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT julieniemela auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT markraffeld auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT helenfmatthews auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT angelawang auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT angelawang auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT pamelaangelus auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT pamelaangelus auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT helencsu auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT brucedmazer auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT brucedmazer auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT andrewlsnow auniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT marylindesjardins uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT marylindesjardins uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT swadhinyaarjunaraja uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT jeffreyrstinson uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT batsukhdorjbal uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT jananisundaresan uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT julieniemela uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT markraffeld uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT helenfmatthews uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT angelawang uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT angelawang uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT pamelaangelus uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT pamelaangelus uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT helencsu uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT brucedmazer uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT brucedmazer uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
AT andrewlsnow uniqueheterozygouscard11mutationcombinespathogenicfeaturesofbothgainandlossoffunctionpatientsinafourgenerationfamily
_version_ 1725825564604891136
spelling doaj-27da10c6f70a47b49f5c81ba79866af42020-11-24T22:05:36ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-12-01910.3389/fimmu.2018.02944414125A Unique Heterozygous CARD11 Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation FamilyMarylin Desjardins0Marylin Desjardins1Swadhinya Arjunaraja2Jeffrey R. Stinson3Batsukh Dorjbal4Janani Sundaresan5Julie Niemela6Mark Raffeld7Helen F. Matthews8Angela Wang9Angela Wang10Pamela Angelus11Pamela Angelus12Helen C. Su13Bruce D. Mazer14Bruce D. Mazer15Andrew L. Snow16Division of Allergy and Immunology, Department of Paediatrics, McGill University Health Centre, Montreal, QC, CanadaMeakins-Christie Laboratories of the Research Institute of the McGill University Health Centre, Montreal, QC, CanadaDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of Health Sciences, Bethesda, MD, United StatesDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of Health Sciences, Bethesda, MD, United StatesDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of Health Sciences, Bethesda, MD, United StatesDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of Health Sciences, Bethesda, MD, United StatesDepartment of Laboratory Medicine, NIH Clinical Center, Bethesda, MD, United StatesLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesLaboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United StatesLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United StatesClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., National Cancer Institute at Frederick, Frederick, MD, United StatesLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United StatesClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., National Cancer Institute at Frederick, Frederick, MD, United StatesLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United StatesDivision of Allergy and Immunology, Department of Paediatrics, McGill University Health Centre, Montreal, QC, CanadaMeakins-Christie Laboratories of the Research Institute of the McGill University Health Centre, Montreal, QC, CanadaDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of Health Sciences, Bethesda, MD, United StatesCARD11 is a lymphocyte-specific scaffold molecule required for proper activation of B- and T-cells in response to antigen. Germline gain-of-function (GOF) mutations in the CARD11 gene cause a unique B cell lymphoproliferative disorder known as B cell Expansion with NF-κB and T cell Anergy (BENTA). In contrast, patients carrying loss-of-function (LOF), dominant negative (DN) CARD11 mutations present with severe atopic disease. Interestingly, both GOF and DN CARD11 variants cause primary immunodeficiency, with recurrent bacterial and viral infections, likely resulting from impaired adaptive immune responses. This report describes a unique four-generation family harboring a novel heterozygous germline indel mutation in CARD11 (c.701-713delinsT), leading to one altered amino acid and a deletion of 4 others (p.His234_Lys238delinsLeu). Strikingly, affected members exhibit both moderate B cell lymphocytosis and atopic dermatitis/allergies. Ectopic expression of this CARD11 variant stimulated constitutive NF-κB activity in T cell lines, similar to other BENTA patient mutations. However, unlike other GOF mutants, this variant significantly impeded the ability of wild-type CARD11 to induce NF-κB activation following antigen receptor ligation. Patient lymphocytes display marked intrinsic defects in B cell differentiation and reduced T cell responsiveness in vitro. Collectively, these data imply that a single heterozygous CARD11 mutation can convey both GOF and DN signaling effects, manifesting in a blended BENTA phenotype with atopic features. Our findings further emphasize the importance of balanced CARD11 signaling for normal immune responses.https://www.frontiersin.org/article/10.3389/fimmu.2018.02944/fullCARD11BENTAAtopyB cell lymphocytosisprimary immumunodeficiencies